https://www.nabtrade.com.au/investor/insights/latest-news/news/2018/01/4_promising_biotechs
immutep is at the forefront of the approach of harnessing the immune system’s abilities as the future frontier of cancer treatment, with a particular focus on combination therapies. Major global pharmaceutical companies are backing LAG-3 as a meaningful therapeutic target, leaving IMM nicely positioned as the intellectual property owner.
And still we wait for this to reflect on the SH price!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $396.3M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.3¢ | 27.0¢ | $466.6K | 1.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 448593 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 150259 | 4 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| IMM (ASX) Chart |